Wire · operational-macro
FDA Approves Talazoparib With Enzalutamide for Certain Metastatic HRR-Mutated Prostate Cancers
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 October 2026 · Fusion42 review
The FDA has approved the combination of talazoparib and enzalutamide for treating adults with metastatic androgen pathway modulation–naive or –sensitive prostate cancer with homologous recombination repair (HRR) gene mutations, based on evidence from the TALAPRO-3 trial showing significant improvement in radiographic progression-free survival.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 7 sources have reported it.
◆ ◆ The Wire takeaway
You face a new approved therapy route for metastatic HRR-mutated prostate cancer, opening market access and clinical demand for combination drugs using talazoparib and enzalutamide. Clinical ventures in diagnostics or treatment now must align with FDA-authorized tests and trial-backed protocols to compete.
◆ Coverage
7 sources · 26 Oct 2026
◆ Related on Wire
◆ Topics